[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"crc-colorectal-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:crc-colorectal-cancer":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,25,0,[8,44,67,119,171,210,242,269,296,321,346,368,388,414,438,462,491,516,547,569,592,616,636,655,675],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100614842","phase-3-a-study-to-evaluate-the-efficacy-and-safety-of-standard-of-care-chemotherapy-and-bevacizumab-with-or-without-inca33890-in-the-first-line-treatment-of-metastatic-microsatellite-stable-colorectal-cancer-100614842",false,"NCT07284849","A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer","A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer","Inclusion Criteria:\n\n* Stage IV colorectal adenocarcinoma not amenable to curative resection.\n* No prior systemic treatment for unresectable or metastatic disease. Participants who received adjuvant or neoadjuvant therapy may enroll if there was no recurrence within 12 months of the end of treatment.\n* Measurable disease per RECIST v1.1.\n* ECOG performance status of 0 or 1.\n* Adequate organ function determined by laboratory results.\n\nExclusion Criteria:\n\n* MSI-H\u002FdMMR per historical data in the medical record.\n* BRAF V600E mutation per historical data in the medical record.\n* Untreated and\u002For progressing CNS metastases.\n* History of other malignancy within 2 years.\n* Treatment with an anti-PD-(L)1 or other immune checkpoint inhibitor for any indication within the last 3 years.\n* Active autoimmune disease that has required systemic treatment in the past 2 years.\n* Significant concurrent and\u002For uncontrolled medical condition.\n* History of organ transplant, including allogeneic stem cell transplantation.\n\nOther protocol-defined inclusion\u002Fexclusion criteria apply.","ALL","18 Years",{"count":19,"type":20},700,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","The purpose of this study is to evaluate the efficacy and safety of standard-of-care chemotherapy and bevacizumab with or without INCA33890 in the first-line treatment of metastatic microsatellite stable colorectal cancer.",[26],"CRC (Colorectal Cancer)",[28,29,30],"Metastatic Colorectal Cancer","Colon Cancer","INCA33890","RECRUITING","2026-06-29",{"date":34,"type":35},"2026-06-30","ACTUAL",{"date":37,"type":35},"2026-03-05",{"date":39,"type":20},"2029-09-28",{"name":41,"class":42},"Incyte Corporation","INDUSTRY",275,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":4},"100644374","monocentric-retrospective-and-prospective-observational-study-of-patients-with-colorectal-cancer-100644374","NCT07663162","Monocentric Retrospective and Prospective Observational Study of Patients With Colorectal Cancer","CRC-R","Inclusion Criteria:\n\n1. Participant is willing and able to give informed and written consent for the participation in the study\n2. Patients affected by colorectal neoplasm (regardless of disease stage)\n3. Aged \\> 18 years\n4. Patients in clinical conditions permissive to adhere to the diagnostic-therapeutic program proposed in according to the stage of the disease\n\nExclusion Criteria:\n\n1. Pediatric population\n2. Pre-existing conditions or concurrent diagnoses that would preclude the participant's full adherence with or completion of the study\n3. Pregnancy",{"count":52,"type":20},2000,"OBSERVATIONAL","Monocentric retrospective and prospective observational study of patients with colorectal cancer",[26],"NOT_YET_RECRUITING","2026-06-16",{"date":59,"type":35},"2026-06-23",{"date":61,"type":20},"2026-06",{"date":63,"type":20},"2036-06",{"name":65,"class":66},"IRCCS San Raffaele","OTHER",{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":74,"targetDuration":4,"studyType":21,"phases":76,"briefSummary":78,"conditions":79,"keywords":84,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":118},"100580305","phase-1-a-study-to-learn-about-study-medicine-alta3263-in-adults-with-advanced-solid-tumors-with-kras-mutations-100580305","NCT06835569","A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations","A Phase 1\u002F1b Multiple Cohort Trial of ALTA3263 in Patients With Advanced Solid Tumors With KRAS Mutations","Inclusion Criteria:\n\n* Histologically confirmed diagnosis of a solid tumor malignancy harboring a KRAS mutation identified through molecular testing (NGS- or PCR-based) with a Clinical Laboratory Improvement Amendments-certified (or equivalent) diagnostic test.\n* Unresectable or metastatic disease.\n* Progressed on, intolerant to, or declined prior standard-of-care therapy (including targeted therapy, if applicable) appropriate to tumor type and stage\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Adequate organ function\n\nExclusion Criteria:\n\n* Prior treatment with a KRAS inhibitor, certain exceptions are described in the full study protocol\n* Known condition that prohibits the ability to swallow or absorb an oral medication.\n\nOther inclusion\u002Fexclusion criteria may apply.",{"count":75,"type":20},448,[77],"PHASE1","The purpose of this study is to characterize the safety and tolerability of ALTA3263 in adults with advanced solid tumors with KRAS mutations.",[80,81,82,26,83],"Cancer","PDAC - Pancreatic Ductal Adenocarcinoma","NSCLC (Non-small Cell Lung Cancer)","Advanced Solid Tumors",[85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108],"KRAS mutation","NSCLC","Non-small cell lung cancer","Colorectal cancer","Pancreatic ductal adenocarcinoma","Colorectal carcinoma","Pancreatic cancer","Pancreatic carcinoma","Solid tumors","KRAS","Mutation","Metastatic","Advanced unresectable","Neoplasms","Neoplasms by Site","Carcinoma","Non-small cell lung carcinoma","Non-small cell lung neoplasm","Pancreatic neoplasm","Lung neoplasm","Colorectal neoplasm","Colon neoplasm","Mutant KRAS","KRAS amplification","2026-06-08",{"date":111,"type":35},"2026-06-10",{"date":113,"type":35},"2025-03-05",{"date":115,"type":20},"2029-08",{"name":117,"class":42},"Alterome Therapeutics, Inc.",12,{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":126,"targetDuration":4,"studyType":21,"phases":128,"briefSummary":129,"conditions":130,"keywords":142,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":170},"100586569","phase-1-bbo-11818-in-adult-subjects-with-kras-mutant-cancer-100586569","NCT06917079","BBO-11818 in Adult Subjects With KRAS Mutant Cancer","A Phase 1a\u002F1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-11818 in Subjects With Advanced KRAS Mutant Cancers","Inclusion Criteria:\n\n* Histologically documented locally advanced and unresectable or metastatic NSCLC, PDAC, CRC, or other solid tumor with KRAS G12A, G12C, G12D, G12S, or G12V mutation\n* Measurable disease by RECIST v1.1\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1\n* Life expectancy \\>24 weeks\n* Adequate organ function\n\nExclusion Criteria:\n\n* Malignancy within the last 2 years as specified in the protocol\n* Untreated brain metastases\n\nOther inclusion\u002Fexclusion criteria are specified in the protocol.",{"count":127,"type":20},665,[77],"A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumors.",[131,86,81,26,132,133,134,135,136,137,138,139,140,141],"Non-Small Cell Lung Cancer","Metastatic Non-Small Lung Cell Cancer","Metastatic Colorectal Cancer (CRC)","KRAS G12A","KRAS G12C","KRAS G12D","KRAS G12S","KRAS G12V","Metastatic Pancreatic Ductal Adenocarcinoma","Advanced Lung Carcinoma","Solid Tumor, Adult",[143,144,145,146,86,147,148,149,150,151,152,153,154,155,156,157,158,159,160],"BBOT","BridgeBio Oncology Therapeutics","Phase1","Phase 1a\u002F1b","CRC","PDAC","Metastatic Cancer","Advanced Cancer","Pembrolizumab","Cetuximab","Platinum Chemotherapy","Pemetrexed","KONQUER","KONQUER-101","mFOLFOX6","mFOLFIRINOX","Gemcitabine","Nab-paclitaxel","2026-05-29",{"date":163,"type":35},"2026-06-02",{"date":165,"type":35},"2025-03-31",{"date":167,"type":20},"2029-09",{"name":169,"class":42},"TheRas, Inc., d\u002Fb\u002Fa BBOT (BridgeBio Oncology Therapeutics)",17,{"id":172,"slug":173,"hasResults":11,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":4,"eligibilityCriteria":177,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":178,"targetDuration":4,"studyType":21,"phases":180,"briefSummary":181,"conditions":182,"keywords":189,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":209},"100599484","phase-1-a-first-in-human-study-of-alx2004-with-advanced-or-metastatic-selected-solid-tumors-100599484","NCT07085091","A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors","A Phase 1, First in Human, Open-Label Multicenter Study to Evaluate ALX2004, an Antibody Drug Conjugate Targeting EGFR in Participants With Advanced or Metastatic Select Solid Tumors","Inclusion Criteria:\n\n* Participants with locally advanced, recurrent or metastatic histologically confirmed HNSCC, NSCLC, ESCC, CRC; locally advanced or recurrent disease must not be amenable to resection with curative intent\n\n  1. Dose Escalation: Participants who have relapsed or progressed following prior anticancer therapy in the advanced\u002Fmetastatic setting and for whom no approved or standard therapy is available.\n  2. Dose Exploration and Dose Expansion: The following tumor-specific criteria also apply. These cohorts will include all or a subset of these tumors.\n\nHNSCC - Received no more than 3 prior lines of therapy in the advanced or metastatic setting\n\nNSCLC - For participants with a targetable molecular alteration: received appropriate standard targeted therapy and no more than 2 prior lines of systemic chemotherapy in the advanced\u002Fmetastatic setting. For participants without a targetable molecular alteration: received platinum-based chemotherapy and CPI (in combination or separately), and have received no more than 2 prior lines of systemic chemotherapy in the advanced\u002Fmetastatic setting\n\nESCC - Received no more than 3 prior lines of therapy in the advanced\u002Fmetastatic setting\n\nCRC - For participants with a targetable molecular alteration (including dMMR or MSI-H): Received appropriate standard therapy for the alteration, at least 2 prior lines of systemic chemotherapy, and no more than 4 prior lines of therapy in the advanced\u002Fmetastatic setting. For participants without a targetable molecule alteration: Received at least 2 prior lines of systemic chemotherapy (including an oxaliplatin-based chemotherapy), vascular endothelial growth factor (VEGF)-based therapy, and no more than 4 prior lines of therapy in the advanced\u002Fmetastatic setting.\n\n* Adequate Bone Marrow Function\n* Adequate Renal \\& Liver Function\n* Adequate Performance Status\n\nExclusion Criteria:\n\n* Participants with disease suitable for local therapy with curative intent.\n* Has a life expectancy of less than 3 months and\u002For has rapidly progressing disease (e.g., tumor bleeding, uncontrolled tumor pain) in the opinion of the treating investigator\n* Prior treatment with any ADCs that have an active TOP1 inhibitor-based component",{"count":179,"type":20},170,[77],"A Phase 1, First in Human, Open-Label Multicenter Study to Evaluate ALX2004, an Antibody Drug Conjugate Targeting EGFR in Participants with Advanced or Metastatic Select Solid Tumors",[183,184,26,185,186,187,188],"NSCLC (Advanced Non-small Cell Lung Cancer)","HNSCC","ESCC","Colo-rectal Cancer","Head and Neck Cancer","Esophageal Squamous Cell Carcinoma (ESCC)",[190,191,192,193,194,195,184,147,196,197,198,199],"ALX2004","EGFR","Solid Tumors","metastatic","Antibody Drug Conjugate","ADC","Lung","Non small cell lung cancer","esophageal","EGFR ADC","2026-05-11",{"date":202,"type":35},"2026-05-12",{"date":204,"type":35},"2025-08-18",{"date":206,"type":20},"2027-12",{"name":208,"class":42},"ALX Oncology Inc.",8,{"id":211,"slug":212,"hasResults":11,"nctId":213,"briefTitle":214,"officialTitle":214,"acronym":215,"eligibilityCriteria":216,"healthyVolunteers":11,"sex":16,"minAge":217,"maxAge":218,"enrollmentInfo":219,"targetDuration":4,"studyType":21,"phases":221,"briefSummary":223,"conditions":224,"keywords":226,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":241},"100612540","feasibility-of-a-multi-channel-intervention-to-promote-colorectal-cancer-screening-among-american-indians-in-oklahoma-100612540","NCT07254910","Feasibility of a Multi-Channel Intervention to Promote Colorectal Cancer Screening Among American Indians in Oklahoma","YVONNE","Inclusion Criteria:\n\n* Age 45-75 Live within IHS Clinton Service Unit catchment area Fluent in English and read at or above 6th grade level Self report as American Indian or have CDIB\n\nExclusion Criteria:\n\n* Self report up to date with CRC screening FIT within 1 year","45 Years","75 Years",{"count":220,"type":20},150,[222],"NA","The Accelerating Colorectal Cancer Screening and follow-up through Implementation Science (ACCSIS) Program addresses major regional CRC screening disparities among AI in Oklahoma. The investigators are engaged in a participatory and collaborative effort with Tribal Nations, Area Indian Health Boards, and Indian Health Service (IHS) healthcare facilities. The overall objective of this proposal is to leverage these relationships and examine the feasibility of co-developing and disseminating a v-TCHE as part of a multi-channel communication intervention. To achieve this objective, the investigators have partnered with IHS Clinton Service Unit, which serves members of the Cheyenne and Arapaho Tribes. The intervention will be disseminated across two channels: (1) Social Media (i.e., accessed via online study adverts) and (2) Clinic (i.e., direct messaging to patients via a study link in a SMS text). Across both channels, the investigators will examine reach of the intervention and its potential efficacy via a randomized controlled trial. Once participants click on the study link they will be randomized 1:1 to one of two intervention conditions: (1) watch a Narrative Testimonial Video of a real-life Tribal community health educator (control) or (2) an interaction with a v-TCHE. Participants will then complete a post-intervention survey, in which they can click to order a FIT kit afterwards.",[225,26],"CRC Screening",[227,228,229,230,231],"colorectal screening","virtual clinician","multi-channel communication","tribal outreach","Tribal Nations","2026-04-22",{"date":234,"type":35},"2026-04-23",{"date":236,"type":20},"2026-05-30",{"date":238,"type":20},"2026-09-30",{"name":240,"class":66},"University of Oklahoma",1,{"id":243,"slug":244,"hasResults":11,"nctId":245,"briefTitle":246,"officialTitle":246,"acronym":247,"eligibilityCriteria":248,"healthyVolunteers":249,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":250,"targetDuration":4,"studyType":21,"phases":252,"briefSummary":253,"conditions":254,"keywords":257,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":261,"lastUpdatePostDateStruct":262,"startDateStruct":263,"completionDateStruct":265,"leadSponsor":267,"locationsCount":241},"100589638","a-prospective-study-to-evaluate-the-performance-of-a-real-time-system-in-the-estimation-of-colorectal-polyp-size-100589638","NCT06957015","A Prospective Study to Evaluate the Performance of a Real-time System in the Estimation of Colorectal Polyp Size","EndoAIM","Inclusion Criteria:\n\nSubjects are eligible if:\n\n1. They have received colonoscopy for screening, surveillance or symptom investigation;\n2. Aged 18 years older or above;\n3. Written informed consent obtained.\n\nExclusion Criteria:\n\nSubjects are excluded if they have:\n\n1. Contraindication to colonoscopy (e.g. intestinal obstruction or perforation)\n2. Contraindication or conditions precluding polyp resection (e.g. active gastrointestinal bleeding, uninterrupted anticoagulation or dual antiplatelets)\n3. Advanced comorbid conditions (defined as American Society of Anesthesiologists grade 4 or above)",true,{"count":251,"type":20},278,[222],"Colorectal polyp size is related to the risk of exhibiting advanced histological features. Moreover, polyps larger than 10 mm are associated with an elevated risk of metachronous advanced neoplasia and colorectal cancer (CRC). Consequently, accurate measurement of polyp size, especially at the 10 mm threshold is critical for risk stratification and surveillance intervals. Furthermore, polyp size is also important for the choice of the appropriate resection procedures. Underestimation may lead to delayed diagnosis, thereby increasing the risk of colorectal cancer, while overestimation may result in unnecessary surveillance endoscopies.",[255,26,256],"Colonic Polyps","Artificial Intelligence (AI)",[258,259,260],"artificial intelligence","polyp size measurement","surveillance intervals","2026-04-20",{"date":234,"type":35},{"date":264,"type":35},"2025-05-13",{"date":266,"type":20},"2028-01-01",{"name":268,"class":66},"Chinese University of Hong Kong",{"id":270,"slug":271,"hasResults":11,"nctId":272,"briefTitle":273,"officialTitle":274,"acronym":4,"eligibilityCriteria":275,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":276,"targetDuration":4,"studyType":21,"phases":278,"briefSummary":279,"conditions":280,"keywords":284,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":261,"lastUpdatePostDateStruct":288,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":293,"locationsCount":295},"100571494","phase-1-a-study-to-investigate-the-safety-and-efficacy-of-kqb365-as-monotherapy-and-in-combination-in-participants-with-advanced-solid-malignancies-100571494","NCT06720987","A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies","A Phase 1\u002F1b, Open-label, Multicenter, Dose Escalation and Dose Optimization Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of KQB365 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies With KRAS G12S or G12C Mutations","Inclusion Criteria:\n\n* PART 1 (monotherapy and combo therapy with KQB198): Histologically confirmed diagnosis of a solid tumor malignancy with either a KRAS G12C or KRAS G12S mutation.\n* PART 1 (combo therapy with Cetuximab) \\& PART 2: Histologically confirmed diagnosis of adenocarcinoma of the colon or rectum with either a KRAS G12C or KRAS G12S mutation.\n* Unresectable or metastatic disease\n* No available treatment with curative intent\n* Adequate organ function\n* Measurable disease per RECIST v1.1\n\nExclusion Criteria:\n\n* Active primary central nervous system tumors\n* Cardiac abnormalities\n* Active interstitial lung disease\n* Unable to swallow or GI condition that prevents absorption for patients in KQB198 combination cohorts",{"count":277,"type":20},140,[77],"The goal of this clinical trial is to learn if KQB365 works to treat advanced solid tumor cancer in adults. It will also learn about the safety of KQB365. The main questions it aims to answer are:\n\n* What is the safe dose of KQB365 by itself, in combination with cetuximab, or in combination with KQB198?\n* Does KQB365 alone, in combination with cetuximab, or in combination with KQB198 decrease the size of the tumor?\n* What happens to KQB365 in the body?\n\nParticipants will:\n\n* Receive KQB365 infusion weekly alone, in combination with cetuximab, or in combination with oral KQB198.\n* Visit the clinic about 9 times in the first 6 weeks, and then once every week after that.",[281,282,283,26],"KRAS G12C Mutation","KRAS G12S Mutation","Solid Tumor Malignancies",[285,286,287],"cetuximab","KQB365","KQB198",{"date":234,"type":35},{"date":290,"type":35},"2025-02-04",{"date":292,"type":20},"2030-06-30",{"name":294,"class":42},"Kumquat Biosciences Inc.",11,{"id":297,"slug":298,"hasResults":11,"nctId":299,"briefTitle":300,"officialTitle":301,"acronym":302,"eligibilityCriteria":303,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":304,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":306,"conditions":307,"keywords":309,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":312,"lastUpdatePostDateStruct":313,"startDateStruct":315,"completionDateStruct":317,"leadSponsor":319,"locationsCount":4},"100631216","smyd3-driven-metabolic-rewiring-in-colorectal-liver-metastases-100631216","NCT07497789","SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases","Targeting SMYD3-Driven Metabolic Rewiring and Oxidative Stress Adaptation in Colorectal Liver Metastases","AIRC_ IG 34634","Inclusion Criteria:\n\nCommon criteria\n\n* Age ≥ 18 years.\n* Availability of residual tumor tissue from the surgical procedure that is not required for diagnostic purposes.\n* Signed written informed consent for the use of biological samples for research purposes.\n\nCohort\u002FArm 1 (Colon-rectal tumor resection)\n\n\\- Patients undergoing surgical resection of colorectal cancer.\n\nCohort\u002FArm 2 (Primary tumor and liver metastases resection) - Patients undergoing surgical resection of the primary colorectal tumor and liver metastases from colorectal carcinoma.\n\nCohort\u002FArm 3 (Liver metastases resection only)\n\n\\- Patients undergoing surgical resection of liver metastases from colorectal carcinoma previously resected at the primary site.\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years.\n* Undergoing surgical intervention for a malignancy other than those specified in the inclusion criteria.\n* Lack of signed informed consent",{"count":305,"type":20},156,"This study focuses on patients with colorectal cancer undergoing surgery for the primary tumor and\u002For liver metastases. Tumor samples collected during surgery will be used to generate patient-derived models (primary cultures, spheroids, and organoids) to study colorectal cancer stem cells. The main objective is to investigate the role of the lysine methyltransferase SMYD3 in metabolic reprogramming and adaptation to oxidative stress that enable colorectal cancer cells to survive and grow in the liver. Previous work has shown that SMYD3 is overexpressed in colorectal cancer, promotes drug resistance, and regulates key oncogenic pathways, including c-MYC and the AMPK\u002FmTOR axis. By identifying SMYD3-dependent pathways and pharmacologic vulnerabilities in cancer stem cells within liver metastases, this study aims to support the development of new therapeutic strategies that combine SMYD3 inhibitors with approved or experimental agents targeting tumor metabolism and oxidative stress responses",[26,308],"Liver Metastases From Colorectal Primary Cancer",[88,310,311],"liver metastases","liver metastases from colorectal cancer","2026-03-31",{"date":314,"type":35},"2026-04-06",{"date":316,"type":20},"2026-05-10",{"date":318,"type":20},"2028-05-10",{"name":320,"class":66},"Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis",{"id":322,"slug":323,"hasResults":11,"nctId":324,"briefTitle":325,"officialTitle":326,"acronym":4,"eligibilityCriteria":327,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":328,"targetDuration":4,"studyType":21,"phases":330,"briefSummary":332,"conditions":333,"keywords":336,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":337,"lastUpdatePostDateStruct":338,"startDateStruct":340,"completionDateStruct":342,"leadSponsor":343,"locationsCount":345},"100595482","phase-2-an-evaluation-of-ngm120-in-a-randomized-double-blind-placebo-controlled-study-in-participants-with-colorectal-cancer-who-have-cancer-cachexia-100595482","NCT07033026","An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.","A Phase 2, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of NGM120 in Participants With Colorectal Cancer Who Have Cancer Cachexia","Inclusion Criteria:\n\n1. Documented active diagnosis of colorectal cancer.\n2. Cachexia defined by Fearon criteria of weight loss.\n3. Signed informed consent.\n\nExclusion Criteria:\n\n1. Current active reversible causes of decreased food intake.\n2. Receiving tube feedings or parenteral nutrition at the time of Screening or Randomization.\n3. Have cachexia caused by other reasons.",{"count":329,"type":20},136,[331],"PHASE2","A multi-center evaluation of NGM120 in a randomized, double-blind, placebo-controlled study in participants with colorectal cancer who have cancer cachexia.",[334,26,335],"Colorectal Cancer","Cancer Cachexia",[335,334,147],"2026-03-30",{"date":339,"type":35},"2026-04-01",{"date":341,"type":35},"2025-06-25",{"date":206,"type":20},{"name":344,"class":42},"NGM Biopharmaceuticals, Inc",28,{"id":347,"slug":348,"hasResults":11,"nctId":349,"briefTitle":350,"officialTitle":351,"acronym":352,"eligibilityCriteria":353,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":218,"enrollmentInfo":354,"targetDuration":4,"studyType":21,"phases":356,"briefSummary":357,"conditions":358,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":359,"lastUpdatePostDateStruct":360,"startDateStruct":362,"completionDateStruct":364,"leadSponsor":366,"locationsCount":241},"100629750","phase-2-neoadjuvant-shr-1701-plus-chemoradiotherapy-for-locally-advanced-rectal-cancer-100629750","NCT07478731","Neoadjuvant SHR-1701 Plus Chemoradiotherapy for Locally Advanced Rectal Cancer","A Phase II, Prospective, Single Arm Study of Neoadjuvant SHR-1701 Combine With Chemoradiotherapy for Locally Advanced Rectal Cancer","MA-CRC-II-018","Inclusion Criteria:\n\n* 1: Sign the informed consent form and voluntarily participate in this study\n\n  2: Age 18-75\n\n  3: Pathologically confirmed rectal adenocarcinoma（At least meet any of the following criteria：cT3-4、cN2、EMVI+、MRF+）\n\n  4: pMMR or MSS\u002FMSI-L rectal adenocarcinoma\n\n  5: The distance from tumor edge to the anal verge\n\n  6: Expect to complete R0 resection\n\n  7: Patients can swallow pills\n\n  8: ECOG PS 0-1\n\n  9: Patients has not received any anti-tumor treatment before, including surgery, radiotherapy, chemotherapy, targeting therapy and immunotherapy\n\n  10: Plan to complete surgery after neoadjuvant therapy\n\n  11: There is contraindication to surgery\n\n  12: Main organ function efficient, including blood routine examination, blood biochemical examination, coagulation function\n\n  13: Female subjects with reproductive capacity are required to undergo a serum pregnancy test 72 hours before starting the administration of the test drug, and the result must be negative. During the trial period and for at least 3 months after the last administration, they must take effective contraceptive measures (such as intrauterine devices, contraceptives, or condoms). For male subjects whose partners are female with reproductive capacity, effective contraceptive measures must be taken during the trial period and for at least 3 months after the last administration.\n\nExclusion Criteria:\n\n1. Allergy to monoclonal antibody, SHR-1701, capecitabine, oxaliplatin and other platinum drugs\n2. The patient previously received or is receiving any following treatments: a) Any surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy, etc; b) Within 2 weeks before the first use of the study drug, is using immunosuppressive drugs or systemic hormone drugs to achieve immunosuppression (dose \\> 10mg\u002Fday prednisone or equivalent); in the absence of active autoimmune diseases, inhalation or local use of steroids and doses \\> 10mg\u002Fday prednisone or equivalent adrenal cortical hormones are allowed; c) Has received attenuated live vaccines within 4 weeks before the first use of the study drug; d) Has undergone major surgery or suffered severe trauma within 4 weeks prior to the first use of the study drug.\n3. Having any active autoimmune disease or a history of autoimmune disease, including but not limited to: interstitial pneumonia, enteritis, hepatitis, pituitary inflammation, vasculitis, nephritis, hyperthyroidism, hypothyroidism (considered for inclusion after hormone replacement therapy); patients with psoriasis or childhood asthma\u002Fallergy that has completely resolved and does not require any intervention after adulthood can be considered for inclusion, but patients who require medical intervention with bronchodilators cannot be included.\n4. Have a history of immunodeficiency, including a positive HIV test result, or suffer from other acquired or congenital immune deficiency diseases, or have a history of organ transplantation or allogeneic bone marrow transplantation.\n5. There are heart diseases or clinical symptoms that are not well controlled, including but not limited to: (1) NYHA grade II or above heart failure, (2) unstable angina pectoris, (3) having experienced myocardial infarction within the past year, (4) having clinically significant supraventricular or ventricular arrhythmias that have not been controlled through clinical intervention or remain poorly controlled even after clinical intervention.\n6. Within 4 weeks prior to the first use of the study drug, there was a severe infection (CTCAE \\> grade 2), such as severe pneumonia, bacteremia, infection complications, etc required hospitalization; those with baseline chest imaging indicating active pulmonary inflammation, those who had symptoms and signs of infection or required oral or intravenous antibiotic treatment within 14 days prior to the first use of the study drug, excluding cases where antibiotics were used prophylactically.\n7. Those who were found to have active tuberculosis infection through medical history or CT examination, or those who had a history of active tuberculosis infection within the previous 1 year of enrollment, or those who had a history of active tuberculosis infection more than 1 year ago but did not receive proper treatment.\n8. There is active hepatitis B (with HBVDNA ≥ 2000 IU\u002FmL or 104 copies\u002FmL) and hepatitis C (with positive hepatitis C antibody and HCVRNA above the detection limit of the analytical method)\n9. If within the 5 years prior to the first use of the investigational drug, one has been diagnosed with any other malignant tumor, except for those with low risk of metastasis or mortality (with a 5-year survival rate \\> 90%), such as fully treated skin basal cell carcinoma, squamous cell carcinoma of the skin, or cervical carcinoma in situ, etc., they may be considered for inclusion.\n10. Pregnant or lactating women\n11. Based on the researchers' assessment, there are other factors that could potentially lead to the premature termination of the study. These include having other serious illnesses (including mental disorders) that require combined treatment, alcohol abuse, drug abuse, family or social factors, which may affect the safety or compliance of the participants.",{"count":355,"type":20},48,[331],"The goal of this clinical trial is to learn if SHR-1701 combine with chemoradiotherapy works to treat severe CRC.\n\nParticipants will take:\n\nInduction: SHR-1701 combined with CAPOX for one cycle. Radiotherapy: Short-course radiotherapy (SCRT) (25Gy\u002F5F). Consolidation: SHR-1701 combined with CAPOX for five cycles, after which the subjects undergo TME surgery.",[26],"2026-03-13",{"date":361,"type":35},"2026-03-17",{"date":363,"type":35},"2025-12-20",{"date":365,"type":20},"2027-12-31",{"name":367,"class":66},"Hong Qiu",{"id":369,"slug":370,"hasResults":11,"nctId":371,"briefTitle":372,"officialTitle":373,"acronym":4,"eligibilityCriteria":374,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":375,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":377,"conditions":378,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":380,"lastUpdatePostDateStruct":381,"startDateStruct":383,"completionDateStruct":385,"leadSponsor":386,"locationsCount":241},"100611321","validation-of-high-throughput-large-format-tissue-preprocessing-for-lung-and-colorectal-cancer-100611321","NCT07239063","Validation of High-Throughput Large-Format Tissue Preprocessing for Lung and Colorectal Cancer","Validation of a High-Throughput, Large-Format, Tissue-Specific Preprocessing Protocol for Lung and Colorectal Cancer","Inclusion Criteria:\n\n1. Patients who have been pathologically diagnosed as having lung cancer or colorectal cancer.\n2. Patients with complete clinical data and tumor tissue materials, including H\\&E slides, paraffin blocks, and discarded ex vivo specimens.\n\nExclusion Criteria:\n\n1.Patients with missing data or specimens not meeting quality control requirements for analysis.",{"count":376,"type":20},1000,"This project aims to employ a sample preprocessing system in conjunction with three-dimensional imaging techniques to generate morphologically more complete, high-resolution datasets for lung and colorectal cancers. Building on systematic experimental optimization of the preprocessing system, the investigators will establish tissue-clearing workflows and transparency assessment criteria specifically for lung and colorectal cancer specimens, and develop and validate an efficient 3D immunofluorescent iterative staining protocol adapted for these tumor types to achieve robust three-dimensional imaging. Successful implementation of this project will enable an in-depth characterization of the spatial morphological features of lung and colorectal cancer pathology, facilitate identification of more effective and precise interventional strategies, and ultimately contribute to improved overall survival for cancer patients. Additionally, the resulting datasets will support prospective validation of two-dimensional pathological models.",[26,379],"Lung Cancer (Diagnosis)","2026-02-08",{"date":382,"type":35},"2026-02-10",{"date":384,"type":35},"2024-10-01",{"date":206,"type":20},{"name":387,"class":66},"Nanfang Hospital, Southern Medical University",{"id":389,"slug":390,"hasResults":11,"nctId":391,"briefTitle":392,"officialTitle":393,"acronym":394,"eligibilityCriteria":395,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":396,"targetDuration":4,"studyType":21,"phases":398,"briefSummary":399,"conditions":400,"keywords":403,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":406,"lastUpdatePostDateStruct":407,"startDateStruct":409,"completionDateStruct":411,"leadSponsor":412,"locationsCount":241},"100621906","phase-1-a-phase-1-study-of-tgi-5-as-monotherapy-and-in-combination-with-nivolumab-in-subjects-with-locally-advancedmetastatic-solid-tumors-100621906","NCT07376707","A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced\u002FMetastatic Solid Tumors","A Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics\u002FPharmacodynamics, and Antitumor Activity of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced\u002FMetastatic Solid Tumors","TGI5","Inclusion Criteria:\n\n* 1\\. Male or female subject age ≥18 years at the time of informed consent. 2. Phase 1a and dose escalation part of Phase 1b: Subjects with histologically or cytologically diagnosed unresectable locally advanced\u002Fmetastatic solid tumors, mainly but not limited to CRC, HCC, melanoma, NSCLC.\n\nDose expansion part of Phase 1b:\n\n* Cohort 1: Subjects with histologically or cytologically diagnosed unresectable locally advanced and\u002For metastatic CRC.\n* Cohort 2: Subjects with histologically or cytologically diagnosed unresectable locally advanced and\u002For metastatic melanoma.\n* Cohort 3: Subjects with histologically or cytologically diagnosed unresectable locally advanced and\u002For metastatic NSCLC.\n* Cohort 4: Subjects with other histologically or cytologically diagnosed unresectable locally advanced\u002Fmetastatic solid tumors.\n\n  3\\. Subjects should have documented progression of disease despite all standard therapy or are intolerant of all standard therapy, or for whom no effective standard therapy exists. (Standard therapies are defined as treatments recommended by local guidelines, including but not limited to, chemotherapy, radiation, target therapies based on mutation status, immunotherapy, and surgery in general).\n\nDose expansion part of Phase 1b:\n\n* Cohort 1: Subjects with unresectable locally advanced and\u002For metastatic CRC o At least 2 prior standard chemotherapy\u002Ftherapy regimens are required with documented progression or intolerability to the treatment.\n\n  * Standard chemotherapy regimens include all the following ones (if eligible and no contraindication): Fluoropyrimidine-containing regimen, and\u002For oxaliplatin-containing regimen, and\u002For irinotecan-containing regimen (treatment with a FOLFIRINOX regimen will count as 2 regimens).\n  * With or without an anti-VEGF therapy (e.g., bevacizumab).\n  * At least one of the anti-EGFR monoclonal antibodies (cetuximab or panitumumab) for KRAS wild-type subjects if clinically indicated.\n  * For subjects with a known microsatellite instability high (MSI-H):\n\n    1. Prior treatment with an at least 2 doses of approved or investigational immune checkpoint inhibitor is required with documented progression or intolerability to the treatment.\n    2. Demonstrated disease progression after immune checkpoint inhibitor treatment as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 (Appendix 5). The initial evidence of disease progression is to be confirmed by a second assessment no less than 4 weeks from the date of the first documented disease progression, in the absence of rapid clinical progression. Once disease progression is confirmed, the initial date of disease progression documentation will be considered the date of disease progression.\n    3. Progressive disease that has been documented within 12 weeks from the last dose of immune checkpoint inhibitor.\n\n       Note: a line of therapy is generally considered \\>2 cycles of exposure to the same regimen followed by radiographically documented progression. Agents that are mechanistically similar (e.g., 5-fluorouracil and capecitabine) and are used interchangeably due to tolerability but not progression may be considered as components of the same regimen upon discussion with the medical monitor.\n  * Subjects must have progressed while receiving or after of the last administration of their last line of standard therapy or be unable to tolerate any of these standard treatments.\n  * Subjects who progressed on\u002Fwithin 3 months of adjuvant therapy with anti-PD-1 antibody will be allowed; subjects who received adjuvant chemotherapy and had recurrence\u002Fprogression with development of unresectable or metastatic disease during or within 6 months of completion of the adjuvant chemotherapy can count this as a line of therapy.\n* Cohort 2: Subjects with anti-PD-(L)1 antibody PD-1 relapsed\u002Frefractory melanoma\n\n  * PD-1 refractory disease as defined as progression on treatment with anti-PD-1 antibody administered either as monotherapy or in combination with other checkpoint inhibitors (anti-CTLA4 antibody or anti-LAG-3 antibody) or other therapies. Anti-PD-1 treatment progression is defined by meeting all of the following criteria:\n\n    1\\) Has received at least 2 doses of an approved or investigational anti-PD-1 antibody with documented progression or intolerability to the treatment.\n\n    2\\) Demonstrated disease progression after anti-PD-1 treatment as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 (Appendix 5). The initial evidence of disease progression is to be confirmed by a second assessment no less than 4 weeks from the date of the first documented disease progression, in the absence of rapid clinical progression. Once disease progression is confirmed, the initial date of disease progression documentation will be considered the date of disease progression.\n\n    3\\) Progressive disease that has been documented within 12 weeks from the last dose of anti-PD-1 antibody.\n  * Subjects who progressed on\u002Fwithin 3 months of adjuvant therapy with anti-PD-1 antibody will be allowed; an adjuvant therapy will count as 1 prior line of therapy if received within the prior 6 months.\n  * For patients with BRAF V600 mutations, treatment with BRAF and MEK inhibitors prior to initiation on trial is required, unless patients are intolerant of BRAF targeted therapy.\n  * Treatment must have been discontinued for disease progression or intolerance to therapy.\n* Cohort 3: Subjects with anti-PD-(L)1 antibody relapsed\u002Frefractory NSCLC\n\n  o Anti-PD-(L)1 antibody refractory disease as defined as progression on treatment with anti-PD-(L)1 inhibitor administered either as monotherapy or in combination with platinum-based chemotherapy or other therapies. Anti PD (L)1 treatment progression is defined by meeting all of the following criteria:\n  1. Has received at least 2 doses of an approved or investigational anti-PD-(L)1 inhibitor with documented progression or intolerability to the treatment.\n  2. Has demonstrated disease progression after anti-PD-(L)1 inhibitor as defined by RECIST v1.1 (Appendix 5). The initial evidence of disease progression is to be confirmed by a second assessment no less than 4 weeks from the date of the first documented disease progression, in the absence of rapid clinical progression. Once disease progression is confirmed, the initial date of disease progression documentation will be considered the date of disease progression.\n  3. Progressive disease has been documented within 12 weeks from the last dose of anti-PD-(L)1 inhibitor.\n\n     o Subjects who progressed on\u002Fwithin 3 months of adjuvant therapy with anti PD (L)1 inhibitor will be allowed; an adjuvant therapy will count as 1 prior line of therapy if received within the prior 6 months.\n\n     o Documented disease progression during or after platinum-based chemotherapy alone or intolerability to the treatment for subjects with contraindications to anti PD (L)1 inhibitors.\n     * Patients with NSCLC with known oncogenic driver (including but not limited to EGFR, ALK, ROS, MET alterations) must have received and progressed past driver-specific therapy.\n     * Treatment must have been discontinued for disease progression or intolerance to therapy.\n* Cohort 4: Subjects with other histologically or cytologically diagnosed unresectable locally advanced\u002Fmetastatic solid tumors All subject in Phase 1b must meet PD-L1 expression ≥1%. 4. Subjects must have at least one evaluable lesion in Phase 1a or at least one measurable lesion in Phase 1b as defined by RECIST v1.1 (Appendix 5) which has not received radiotherapy (or progressive disease after radiotherapy).\n\n  5\\. ECOG PS (Appendix 6) of 0\\~2. 6. Life expectancy ≥3 months. 7. Subjects have sufficient baseline organ function and laboratory data meet the following criteria at enrollment:\n* Hematological (without need for hematopoietic growth factor or transfusion support within 2 weeks prior to enrollment):\n\n  1\\) ANC ≥1.5×109\u002FL. 2) Hemoglobin (HGB) ≥90 g\u002FL. 3) Platelet (PLT) ≥75×109\u002FL.\n* Hepatic:\n\n  1\\) AST and ALT ≤2.5×ULN (≤5×ULN for subjects with liver metastases). 2) Total bilirubin (TBil) ≤1.5×ULN, or TBil ≤3.0×ULN for subjects with liver cancer or liver metastases. Subjects with Gilbert's syndrome may enroll if direct bilirubin ≤1.5×ULN.\n* Renal:\n\n  1\\) Creatinine apparent clearance (CL) \\>50 mL\u002Fmin according to modification Cockcroft-Gault equation (140-age \\[year\\])×body weight \\[kg\\]×1.23×(0.85 if female)\u002Fserum creatinine \\[μmol\u002FL\\]).\n* Coagulation:\n\n  1\\) International normalized ratio (INR) ≤1.5. 2) Activated partial thromboplastin time (APTT) ≤1.5×ULN. 8. Woman of child-bearing potential must have a negative serum pregnancy test within 7 days prior to treatment. A female subject of nonchildbearing potential will have had at least 12 continuous months of natural (spontaneous) amenorrhea, follicle stimulating hormone level ≥40 mIU\u002FmL at screening, and an appropriate clinical profile (e.g., age appropriate, history of vasomotor symptoms), or have had surgical bilateral oophorectomy, hysterectomy, or tubal ligation ≥6 weeks prior to screening.\n\n  9\\. Female subjects of childbearing potential or male subjects with a partner of childbearing potential must agree to use effective contraception at the time of informed consent and continuing through the study until 6 months after the last dose of study treatment (Appendix 4).\n\nExclusion Criteria:\n\n* 1\\. Subject with known active central nervous system (CNS) primary tumor or metastases.\n\nNote: Subject with previously treated CNS primary tumor\u002Fmetastases can participate provided they are clinically stable for at least 2 weeks, have no evidence of new or enlarging brain metastases, and there has been no increase in steroid dose for 14 days prior to the first dose of TGI-5 to manage CNS symptoms. Subjects with carcinomatous meningitis or leptomeningeal spread, or spinal cord compression are excluded regardless of clinical stability.\n\n2\\. History of intercurrent severe chronic or active infections:\n\n1. Subjects with active hepatitis B, defined as: if hepatitis B virus surface antigen (HbsAg) positive, hepatitis B virus (HBV) deoxyribonucleic acid (DNA) assay should be performed, and HBV DNA is above the limit quantification.\n2. Subjects with active hepatitis C, defined as: if hepatitis C virus (HCV) antibody positive, HCV ribonucleic acid (RNA) assay should be performed, and HCV RNA is positive.\n3. Known history of acquired immune deficient syndrome (AIDS) or human immunodeficiency virus (HIV) infection.\n4. Subjects with HIV infection may be eligible if CD4+ T cell counts ≥350 cells\u002FµL and without a history of AIDS-defining opportunistic infections.\n5. Other severe chronic within 4 weeks prior to the first dose of TGI-5, including but not limited to hospitalization for complications of infection, bacteremia, severe pneumonia, or active tuberculosis. Or uncontrolled active infections or unexplained fever \\>38°C within 7 days prior to first dose of TGI-5.\n\n3\\. Has a history of active autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, vasculitis, or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 14 days prior the first dose of study drug.\n\nWith the following exceptions: clinically stable autoimmune thyroid disease; treatment with inhaled or topical corticosteroids such as ocular, intra-articular, and intranasal ≤10 mg daily of prednisone equivalent; short-term use of corticosteroids (no more than 7 days) for prophylaxis (e.g., to prevent contrast medium allergy or non-autoimmune allergic diseases); and replacement therapy (e.g., thyroxine for hypothyroidism, insulin for diabetes, physiologic corticosteroid replacement for adrenal or pituitary insufficiency).\n\n4\\. Has a history of symptomatic interstitial lung disease. 5. Toxicities of prior therapies have not been resolved to Grade ≤1 or baseline as per NCI-CTCAE v5.0, except for alopecia, skin hyperpigmentation, Grade 2 neuropathy and Grade 2 endocrinopathy that is well controlled by replacement therapy.\n\n6\\. Subjects with severe or uncontrolled cardiovascular disorder requiring treatment, including any of the following:\n\n1. New York Heart Association (NYHA) class III or IV congestive heart failure.\n2. Left ventricular ejection fraction (LVEF) \\\u003C50% assessed by multiple-gated acquisition (MUGA) scan or echocardiogram (ECHO).\n3. Mean ECG QT interval corrected by Fridericia's formula (QTcF) \\>480 milliseconds (ms) obtained from triplicate 12-lead ECGs, or congenital long QT syndrome.\n4. Any of the following within 6 months prior to screening: Grade \\>2 ventricular arrhythmia, myocardial infarction, severe\u002Funstable angina (even if controlled with medication), coronary artery bypass graft, congestive heart failure, cerebrovascular accident, or transient ischemic attack.\n5. Presence of uncontrolled hypertension (systolic blood pressure \\>160 mmHg or diastolic blood pressure \\>100 mmHg). Subjects with a history of hypertension are allowed if blood pressure is controlled to within these limits by anti-hypertensive treatment.\n6. Symptomatic pulmonary embolism within 6 months prior to initiation of study treatment.\n\n7\\. Prior allogenic or autologous bone marrow transplantation or other solid organ transplantation.\n\n8\\. Has a known additional malignancy that is progressing or has required active treatment within the past 3 years (Note: Subjects with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and localized prostate cancer who have undergone potentially curative therapy. These subjects are not excluded).\n\n9\\. Evidence of clinically significant immunosuppression such as the following:\n\n1. Primary immunodeficiency state such as severe combined immunodeficiency disease (SCID).\n2. Concurrent opportunistic infection. 10. Presence of uncontrolled pleural effusion, pericardial effusion or ascites requiring recurrent drainage procedures (monthly or more frequently).\n\n11\\. Previously treated with the following antitumor therapy (prior to the first dose of TGI-5):\n\n1\\) Previous treated with TIGIT-targeting therapy. 2) Chemotherapy, target therapy, immunotherapy, or other anticancer therapy within 28 days or 5 half-lives, whichever is shorter, prior to the first dose of study treatment, except:\n\n1. Washout period for nitrosoureas or mitomycin is ≤6 weeks.\n2. ≤5 half-lives or 2 weeks (whichever is longer) for fluoropyrimidines or small-molecule targeted agents.\n3. Washout period for herbal therapy with anticancer indications is ≤2 weeks.\n4. Anti-PD-1\u002FPD-L1 antibody therapy within 6 weeks. 3) Prior radiotherapy ≤4 weeks prior to the first dose of study treatment, with the exception of a single fraction of radiotherapy for the purposes of palliation, which is permitted.\n\n   4\\) Subject participated in any other clinical study and has received an investigational product within 28 days prior to the first dose of TGI-5.\n\n   12\\. Has received systematic immunomodulatory drugs within 14 days before the first dose of study drug, such as thymosin, IL-2, and IFN.\n\n   13\\. Has received a live vaccine within 4 weeks prior to the first dose of study drug.\n\n   14\\. Has a recent major surgery within 4 weeks prior to the first dose of study drug or is expected to undergo major surgery during the study.\n\n   15\\. Subject requiring anticoagulant treatment which cannot be safely interrupted, if medically needed for a study procedure (e.g., biopsy) based on the opinion of the investigator.\n\n   16\\. Subjects who have experienced Grade ≥3 irAEs from prior immunotherapies or who discontinue immunotherapy due to immune-related toxicities.\n\n   Note: Subjects with stable hypothyroidism on hormone replacement therapy are eligible.\n\n   17\\. Has a known psychiatric or substance abuse disorder that would interfere with the subject's ability to cooperate with the requirements of the study.\n\n   18\\. Pregnancy or lactation. Women who are willing to discontinue breastfeeding prior to administration of study drug and do not intend to resume breastfeeding may be enrolled.\n\n   19\\. Has known hypersensitivity to either the drug substances or inactive ingredients in the drug product.\n\n   20\\. Pre-existing other serious medical conditions (e.g., active or chronic inflammatory lung disease have not resolved, uncontrolled acute or chronic nephropathy, uncontrolled pancreatitis, uncontrolled hepatopathy, uncontrolled diabetes mellitus, active gastric ulcer, gastrointestinal hemorrhage, uncontrolled epileptic seizure, and signs and symptoms of severe coagulopathy), familial or endemic disease that, in the opinion of the investigator, will interfere with planned staging, treatment, and follow-up, subject compliance, or will place the subject at high risk for treatment-related complications.\n\n   21\\. Subjects who are unwilling or unable to comply with study procedures and study restrictions, or in the judgment of the investigator, would make the subject inappropriate for entry into this study.\n\n   22\\. Subjects who have contraindication for use of PD-1\u002FPD-L1 antibody (only for Phase 1b).",{"count":397,"type":20},194,[77],"This is a Phase 1, multicenter, open-label, two-parts, FIH study to evaluate the tolerability, safety, PK\u002FPD, and preliminary antitumor activity of TGI-5 as monotherapy and in combination with Nivolumab in subjects with unresectable locally advanced\u002Fmetastatic solid tumors.\n\nThe study consists of two parts: TGI-5 monotherapy (Phase 1a: including a dose escalation part and a dose expansion part), TGI-5 in combination with a fixed dose of Nivolumab (Phase 1b: including a dose escalation part and a dose expansion part).",[26,401,402,82],"Melanoma (Skin Cancer)","HCC - Hepatocellular Carcinoma",[404,405],"TGI-5","Locally Advanced\u002FMetastatic Solid Tumors","2026-01-21",{"date":408,"type":35},"2026-01-29",{"date":410,"type":35},"2025-06-12",{"date":365,"type":20},{"name":413,"class":66},"Hefei TG ImmunoPharma Co., Ltd.",{"id":415,"slug":416,"hasResults":11,"nctId":417,"briefTitle":418,"officialTitle":418,"acronym":4,"eligibilityCriteria":419,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":218,"enrollmentInfo":420,"targetDuration":4,"studyType":21,"phases":422,"briefSummary":423,"conditions":424,"keywords":426,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":429,"lastUpdatePostDateStruct":430,"startDateStruct":432,"completionDateStruct":434,"leadSponsor":436,"locationsCount":241},"100619778","phase-1-a-prospective-safety-and-efficacy-clinical-trial-of-pressurized-intraperitoneal-aerosol-therapy-for-peritoneal-metastasis-of-colorectal-cancer-100619778","NCT07349043","A Prospective, Safety, and Efficacy Clinical Trial of Pressurized Intraperitoneal Aerosol Therapy for Peritoneal Metastasis of Colorectal Cancer","Inclusion Criteria:\n\n1. Patients with peritoneal metastatic adenocarcinoma of colorectal origin, confirmed by histopathology, and without metastasis to other sites.\n2. No gender limitation, aged 18 to 75 years old;\n3. ECOG score ≤2;\n4. Subjects without other malignant diseases;\n5. Subjects without laparoscopic surgery contraindications;\n6. Expected survival period \\> 6 months;\n7. Able to comprehend and sign the informed consent form;\n8. The function of important organs should meet the following requirements; The absolute neutrophil count (ANC) is ≥1.5×10\\^9\u002FL; Platelets ≥ 100×10\\^9\u002FL; Hemoglobin ≥8.0g\u002Fdl (Note: It is acceptable to achieve hemoglobin ≥8.0g\u002Fdl through blood transfusion or other interventions); serum albumin ≥2.8g\u002FdL; Bilirubin ≤1.5 times ULN, ALT and AST ≤1.5 times ULN; if there is liver metastasis, ALT and AST ≤5 times ULN; Creatinine clearance rate ≥50mL\u002Fmin\n\nExclusion Criteria:\n\n1. Subjects with gastrointestinal obstruction;\n2. Subjects who rely entirely on parenteral nutrition;\n3. Subjects with decompensated ascites;\n4. Subjects with severe abdominal infection (peritonitis);\n5. Subjects with extensive abdominal adhesion;\n6. Subjects who underwent both tumor reduction surgery and gastrointestinal resection and reconstruction simultaneously;\n7. Subjects with portal vein thrombosis;\n8. Patients with severe or uncontrolled medical conditions and infections (including atrial fibrillation, angina pectoris, heart failure, ejection fraction less than 50%, refractory hypertension, etc.);\n9. Previously allergic to chemotherapy drugs;\n10. Individuals with severe heart and lung, liver and kidney, blood system, or mental illnesses, as well as those who abuse drugs;\n11. Pregnant or lactating women;\n12. Patients who have participated in or are currently participating in other clinical trials within 3 months;\n13. Other situations where the researchers believe that the patient is not suitable to participate in this trial;\n14. Previously had a history of neurological or psychiatric disorders that would affect study informed consent or follow-up evaluation, such as severe depression or dementia;",{"count":421,"type":20},42,[77],"For colorectal cancer with peritoneal metastasis, the current first-line standard treatment offers very limited benefits and short survival. Therefore, it is necessary to seek new treatment strategies to improve the prognosis and survival of such patients. Based on previous basic research and early clinical research results, the strategy of PIPAC combined with MMC or RTX provides a feasible solution that can benefit patients with advanced colorectal cancer and peritoneal metastasis undergoing first-line treatment. This study aims to evaluate the effectiveness of PIPAC combined with MMC or RTX as first-line treatment for patients with colorectal cancer and peritoneal metastasis, while ensuring that patients receive standard first-line treatment. (The main purpose of the proposed Phase I trial is to determine the MTD of PIPAC combined with MMC or RTX and evaluate the safety of combining it with systemic chemotherapy for patients with colorectal cancer and peritoneal metastasis.)",[425,26],"Peritoneal Metastasis",[427,147,428],"peritoneal metastasis","PIPAC","2026-01-08",{"date":431,"type":35},"2026-01-16",{"date":433,"type":20},"2026-01",{"date":435,"type":20},"2028-10",{"name":437,"class":66},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"id":439,"slug":440,"hasResults":11,"nctId":441,"briefTitle":442,"officialTitle":442,"acronym":4,"eligibilityCriteria":443,"healthyVolunteers":249,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":444,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":446,"conditions":447,"keywords":449,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":454,"lastUpdatePostDateStruct":455,"startDateStruct":457,"completionDateStruct":459,"leadSponsor":461,"locationsCount":241},"100604741","identification-of-new-non-invasive-predictive-and-diagnostic-biomarkers-for-colorectal-cancer-100604741","NCT07153458","Identification of New Non-invasive, Predictive, and Diagnostic Biomarkers for Colorectal Cancer","Inclusion Criteria:\n\n* AIM 1: Patients undergoing surgery at the U.O.C. of Surgery, with a diagnosis of CRC.\n* AIM 2: Subjects without colon disease.\n* AIM 3: Subjects with adenoma and high-grade dysplasia.\n\nExclusion Criteria:\n\n* Subject with any other pathology not included in the inclusion criteria.",{"count":445,"type":20},60,"The study in question is an observational study that aims to identify new non-invasive biomarkers present in the serum of patients with CRC and, subsequently, to create a score capable of predicting the development of CRC.\n\nIt is an observational study with 3 enrollment arms:\n\nArm 1: Patients undergoing surgery at the U.O.C. of Surgery, with a CRC diagnosis;\n\nArm 2: Subjects with a negative result from the endoscopic examination;\n\nArm 3: Subjects in whom the presence of an adenoma with high-grade dysplasia is found, a condition considered pre-cancerous.",[26,448],"Adenoma Colon",[450,451,452,453],"crc (colorectal cancer)","Adenoma colon","Biomarkers","neoplasm","2025-12-12",{"date":456,"type":35},"2025-12-19",{"date":458,"type":35},"2025-12-01",{"date":460,"type":20},"2027-12-01",{"name":320,"class":66},{"id":463,"slug":464,"hasResults":11,"nctId":465,"briefTitle":466,"officialTitle":467,"acronym":4,"eligibilityCriteria":468,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":469,"targetDuration":4,"studyType":21,"phases":471,"briefSummary":472,"conditions":473,"keywords":479,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":481,"lastUpdatePostDateStruct":482,"startDateStruct":484,"completionDateStruct":486,"leadSponsor":488,"locationsCount":490},"100505102","phase-1-phase-1-study-evaluating-the-safety-and-pk-of-adu-1805-in-advanced-solid-tumors-100505102","NCT05856981","Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors","An Open-Label, Multicenter, Multi-arm Phase 1 Study Evaluating the Safety and Pharmacokinetics of ADU-1805 in Adults With Advanced Solid Tumors","Inclusion Criteria:\n\n* Male or female aged ≥18 years\n* Signed and dated informed consent form\n* Measurable disease according to RECIST (Safety Expansion only)\n* ECOG Performance status of 0 or 1\n* Adequate organ and marrow function\n* Escalation Phase: Histologically and\u002For cytologically confirmed diagnosis of metastatic or unresectable solid tumors that are refractory to standard therapy or for which no standard therapy exists\n* Expansion Phase: histologically and\u002For cytologically confirmed diagnosis of advanced PD-(L)1-naïve MSS colorectal cancer (CRC), PD-1 relapsed\u002Frefractory patients with either advanced MSS endometrial cancer (EC), renal cell carcinoma (RCC) or non-small cell lung cancer (NSCLC) patients, and that have measurable disease according to RECIST\n\nExclusion Criteria:\n\n* Escalation Phase: Patients that suffer from melanoma, brain tumors, glioblastoma, sarcoma and pancreatic ductal adenocarcinoma (PDAC)\n* Expansion Phase:\n\n  * \\> 3 lines of prior systemic treatments\n  * MSS colorectal cancer (CRC): liver metastasis present\n* Pregnancy or breast-feeding\n* Prior treatment with or receipt of:\n\n  * biological agents, including monoclonal antibodies and immunotherapies, within 28 days prior to the first dose of ADU-1805\n  * chemotherapy, targeted small molecule therapy, hormonal therapy or radiation therapy within 21 days prior to the first dose of ADU-1805 and within 42 days for nitrosoureas and mitomycin C.\n  * anti-SIRPα or anti-CD47-directed therapy\n  * systemic chronic steroid therapy or immunosuppressive therapy within 14 days prior to the first dose of ADU-1805\n  * other investigational new drug or investigational device within 28 days prior to the first dose of ADU-1805\n  * vaccine containing live virus within 28 prior to the first dose of ADU-1805\n* Active untreated brain metastases\n* Active infection requiring systemic therapy\n* Impaired cardiac function or clinically significant cardiac disease\n* Current Grade \\>2 toxicity related to prior anti-cancer therapy\n* History of drug-induced severe immune-related adverse reaction\n* Prior severe hypersensitivity to other monoclonal antibodies or ADU-1805 excipients\n* Major surgery within defined period\n* Diagnosis or positive test of HIV, hepatitis B, hepatitis C, or active tuberculosis\n* Allogenic tissue\u002Fsolid organ transplant\n* Any intercurrent illness that is life-threatening or of such clinical significance that it would interfere with the patient's safety or ability to participate in the study",{"count":470,"type":20},130,[77],"This first-in-human, open-label, multicenter, multi-arm dose-escalation study is designed to evaluate the safety, PK, and PD of ADU-1805, an anti- SIRPα monoclonal antibody, as monotherapy and in combination with pembrolizumab (anti-PD-1 antibody).",[141,474,475,476,477,183,478],"Metastatic Solid Tumor","Refractory Cancer","CRC, Colorectal Cancer","RCC, Clear Cell Adenocarcinoma","Endometrial Cancer",[480],"Immunotherapy","2025-12-09",{"date":483,"type":35},"2025-12-17",{"date":485,"type":35},"2023-04-03",{"date":487,"type":20},"2027-07",{"name":489,"class":42},"Sairopa B.V.",7,{"id":492,"slug":493,"hasResults":11,"nctId":494,"briefTitle":495,"officialTitle":496,"acronym":4,"eligibilityCriteria":497,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":498,"targetDuration":4,"studyType":21,"phases":500,"briefSummary":501,"conditions":502,"keywords":504,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":507,"lastUpdatePostDateStruct":508,"startDateStruct":510,"completionDateStruct":512,"leadSponsor":513,"locationsCount":515},"100612900","phase-1-a-study-of-gfh375-combined-with-cetuximab-or-chemotherapy-in-participants-with-solid-tumors-harboring-kras-g12d-mutation-100612900","NCT07259590","A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation","A Multicenter, Open-Label, Phase Ib\u002FII Clinical Study to Explore the Efficacy, Pharmacokinetics and Safety\u002FTolerability of GFH375 in Combination With Cetuximab or Chemotherapy in Participants With Advanced Solid Tumors Harboring KRAS G12D Mutation","Inclusion Criteria:\n\n1. Voluntarily participate in the study and sign the informed consent form.\n2. Participants receiving Regimen A must be ≥ 18 years old when signing the informed consent form, and participants receiving Arm B must be 18 - 75 years old.\n3. Histologically or cytologically confirmed locally advanced unresectable or metastatic solid tumors, with KRAS G12D mutation.\n4. Failed standard systemic treatment, or intolerant to standard treatment, or unsuitable for standard treatment, or no standard treatment available.\n5. At least one measurable lesions according to RECIST v1.1\n6. Participants receiving Regimen A must have an Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 - 2; participants receiving Regimen B must have an ECOG PS score of 0 - 1.\n7. Have sufficient organ function.\n\nExclusion Criteria:\n\n1. Symptomatic brain metastasis, leptomeningeal metastasis, spinal cord compression, or primary brain tumor.\n2. Presence of known coexisting other cancer driver genes.\n3. Previous or active history of clinically significant cardiovascular dysfunction.\n4. Presence of active infection.\n5. History of central nervous system (CNS) diseases.\n6. Presence of clinically significant interstitial lung disease, radiation pneumonitis, or immune-related pneumonitis requiring treatment.\n7. Newly diagnosed deep vein thrombosis or pulmonary embolism within 3 months before the first administration of the study treatment.\n8. Presence of uncontrolled or symptomatic pleural effusion, ascites, or pericardial effusion.\n9. Having received major surgery within 28 days before the start of the study treatment; having experienced major trauma within 14 days before the start of the study treatment; or planning to undergo major surgery during the study period.\n10. Having received radiotherapy within 4 weeks before the start of the study treatment, or having received palliative radiotherapy for bone metastatic lesions within 2 weeks before the start of the study treatment.",{"count":499,"type":20},126,[77,331],"This is a Phase Ib\u002FII clinical study aimed at exploring the safety and efficacy of Regimen A (GFH375 in combination with Cetuximab) and Regimen B (GFH375 in combination with AG) in participants with solid tumors.Phase Ib: To evaluate the safety\u002Ftolerability and pharmacokinetic (PK) characteristics of GFH375 in combination with cetuximab or AG in participants with solid tumors, and to explore the efficacy of the combination therapy. Phase II: To evaluate the efficacy, safety\u002Ftolerability and PK characteristics of the combination therapy, and to explore the correlation between bio-marker and clinical efficacy.",[503,148,26],"Advanced Solid Tumors Cancer",[505,506],"solid tumors","KRAS G12D Mutations","2025-11-20",{"date":509,"type":35},"2025-12-02",{"date":511,"type":35},"2025-10-21",{"date":487,"type":20},{"name":514,"class":42},"Genfleet Therapeutics (Shanghai) Inc.",4,{"id":517,"slug":518,"hasResults":11,"nctId":519,"briefTitle":520,"officialTitle":521,"acronym":522,"eligibilityCriteria":523,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":524,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":526,"conditions":527,"keywords":528,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":538,"lastUpdatePostDateStruct":539,"startDateStruct":541,"completionDateStruct":543,"leadSponsor":545,"locationsCount":241},"100610227","development-of-a-cfdna-5mc5hmc-based-biomarker-panel-to-predict-targeted-therapy-efficacy-in-mcrc-100610227","NCT07224841","Development of a cfDNA 5mC\u002F5hmC-based Biomarker Panel to Predict Targeted Therapy Efficacy in mCRC","Development of a cfDNA 5mC\u002F5hmC-based Epigenetic Biomarker Panel to Identify Determinants of Response In VEGF\u002FEGFR-targeted Therapy for Metastatic Colorectal Cancer","EpiDRIVE","Inclusion Criteria:\n\n* Histologically confirmed metastatic colorectal adenocarcinoma (mCRC).\n* Received EGFR-targeted therapy (cetuximab\u002Fpanitumumab) or VEGF-targeted therapy (bevacizumab).\n* Availability of pre-treatment plasma sample for cfDNA analysis.\n* Documented radiologic response evaluation (RECIST 1.1).\n* RAS\u002FBRAF mutation status known.\n\nExclusion Criteria:\n\n* Inadequate cfDNA quality or low cfDNA yield.\n* Non-adenocarcinoma histology.\n* Concurrent or prior other active malignancy.\n* Active inflammatory or autoimmune disease affecting cfDNA methylation profiles.",{"count":525,"type":20},500,"The EpiDRIVE study aims to identify cfDNA-based epigenetic determinants of response in metastatic colorectal cancer (mCRC) patients treated with EGFR- or VEGF-targeted therapy.\n\nBy integrating 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC) profiling, this study seeks to develop a predictive biomarker panel capable of differentiating responders from non-responders to targeted therapy.",[26],[529,530,531,532,533,534,535,536,537],"mCRC","Target therapy","5mc\u002F5hmc","5-hydroxymethylation","Metastatic colorectal cancer","anti-EGFR therapy","anti-VEGF therapy","RAS\u002FBRAF mutation","5-methylcytosine","2025-11-03",{"date":540,"type":35},"2025-11-05",{"date":542,"type":35},"2024-06-21",{"date":544,"type":20},"2026-06-18",{"name":546,"class":66},"City of Hope Medical Center",{"id":548,"slug":549,"hasResults":11,"nctId":550,"briefTitle":551,"officialTitle":552,"acronym":553,"eligibilityCriteria":554,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":555,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":557,"conditions":558,"keywords":559,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":538,"lastUpdatePostDateStruct":565,"startDateStruct":566,"completionDateStruct":567,"leadSponsor":568,"locationsCount":241},"100610225","cfdna-5mc5hmc-biomarkers-to-predict-chemotherapy-response-in-metastatic-colorectal-cancer-100610225","NCT07224815","cfDNA 5mC\u002F5hmC Biomarkers to Predict Chemotherapy Response in Metastatic Colorectal Cancer","Development of a cfDNA 5mC\u002F5hmC-based Epigenetic Biomarker Panel to Predict Chemotherapy Efficacy in Metastatic Colorectal Cancer","EpiCORE","Inclusion Criteria:\n\n* Histologically confirmed metastatic colorectal adenocarcinoma (mCRC).\n* Received first-line chemotherapy (FOLFOX or FOLFIRI).\n* Availability of pre-treatment serum or plasma samples for cfDNA 5mC\u002F5hmC analysis.\n* Documented radiologic or clinical response evaluation (RECIST 1.1 or PFS-based).\n* RAS\u002FBRAF mutation status available.\n\nExclusion Criteria:\n\n* Inadequate cfDNA yield or poor DNA quality.\n* Non-adenocarcinoma histology.\n* Active inflammatory or autoimmune disease that may alter cfDNA methylation.\n* Concomitant malignancy requiring systemic therapy.",{"count":556,"type":20},600,"The EpiCORE study aims to identify cfDNA-based epigenetic markers predictive of response to first-line chemotherapy (FOLFOX or FOLFIRI) in metastatic colorectal cancer (mCRC).\n\nBy integrating 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC) profiling, this study seeks to establish a non-invasive biomarker panel capable of distinguishing responders from non-responders.",[26],[147,88,560,561,536,562,563,564],"5mC","5hmC","FOLFOX","FOLFIRI","hydroxymethylation",{"date":540,"type":35},{"date":542,"type":35},{"date":544,"type":20},{"name":546,"class":66},{"id":570,"slug":571,"hasResults":11,"nctId":572,"briefTitle":573,"officialTitle":574,"acronym":4,"eligibilityCriteria":575,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":218,"enrollmentInfo":576,"targetDuration":4,"studyType":21,"phases":578,"briefSummary":579,"conditions":580,"keywords":581,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":584,"lastUpdatePostDateStruct":585,"startDateStruct":587,"completionDateStruct":589,"leadSponsor":591,"locationsCount":241},"100608189","phase-1-a-single-arm-open-label-multicenter-phase-iii-clinical-study-of-gfh276-in-patients-with-ras-mutant-advanced-solid-tumors-100608189","NCT07198321","A Single-Arm, Open-Label, Multicenter Phase I\u002FII Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid Tumors","A Single-Arm, Open-Label, Multicenter Phase I\u002FII Clinical Study","Inclusion Criteria:\n\n1. Subjects must voluntarily agree to participate in the trial and sign a written informed consent form.\n2. Male or female ≥ 18 years old and ≤75 years old.\n3. ECOG performance status of 0-1.\n4. With a life expectancy of ≥3 moths\n5. Have at least one measurable lesion according to RECIST1.1, and the phase Ia allows no measurable lesion.\n6. Adequate laboratory parameters during the screening period.\n\nExclusion Criteria:\n\n1. Active brain metastases.\n2. Prior treatment with a PAN-RAS inhibitor.\n3. Palliative radiotherapy was completed within 14 days before the first dose.\n4. Have poorly controlled or severe cardiovascular disease.\n5. Subjects with active hepatitis B or active hepatitis C.\n6. Known allergy to the study drug or its components.\n7. Pregnant or lactating women.",{"count":577,"type":20},450,[77,331],"This study is an investigation to evaluate the safety\u002Ftolerability, pharmacokinetics (PK), and efficacy of GFH276 as a single agent in patients with advanced solid tumors harboring RAS mutations.\n\nThe primary objectives of the Phase I study are to assess the safety\u002Ftolerability, PK, and preliminary efficacy of GFH276 in patients with advanced solid tumors harboring RAS mutations, and to determine the Maximum Tolerated Dose (MTD) and Recommended Phase II Dose (RP2D) of GFH276.\n\nThe primary objective of the Phase II study is to evaluate the efficacy of GFH276 in patients with RAS-mutant advanced pancreatic ductal adenocarcinoma (PDAC), advanced non-small cell lung cancer (NSCLC), advanced colorectal cancer (CRC), and other advanced solid tumors.",[80,148,26,86],[582,583],"cancer","RAS","2025-09-25",{"date":586,"type":35},"2025-09-30",{"date":588,"type":20},"2025-09-22",{"date":590,"type":20},"2027-12-30",{"name":514,"class":42},{"id":593,"slug":594,"hasResults":11,"nctId":595,"briefTitle":596,"officialTitle":597,"acronym":598,"eligibilityCriteria":599,"healthyVolunteers":11,"sex":16,"minAge":217,"maxAge":218,"enrollmentInfo":600,"targetDuration":4,"studyType":21,"phases":602,"briefSummary":603,"conditions":604,"keywords":605,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":609,"lastUpdatePostDateStruct":610,"startDateStruct":611,"completionDateStruct":613,"leadSponsor":615,"locationsCount":241},"100601851","improving-rates-of-diagnostic-colonoscopy-in-native-americans-100601851","NCT07115875","Improving Rates of Diagnostic Colonoscopy in Native Americans","Improving Rates of Diagnostic Colonoscopy in Native Americans Through a Culturally Sensitive Digital Outreach Intervention","YVONNE-DX","Inclusion Criteria:\n\n* Age 45-75\n* Live in Oklahoma\n* Fluent in English\n* Have access to email\n* Identify as Native American or have a Certificate of Degree of Indian Blood\n\nExclusion Criteria:\n\n\\-",{"count":601,"type":20},164,[222],"Colorectal cancer (CRC) is the second-leading cause of cancer death in both men and women in the United States. Compared to national averages, Native Americans (NA) endure a disproportionate burden of CRC incidence and CRC-specific mortality. The long-term goal of this collaboration is to enhance health equity through the reduction of CRC disparities in morbidity, mortality, stage-at-diagnosis, and survival among NA. To do so, the primary focus of these efforts has been to improve processes that increase uptake of home stool screening. The overall objective is to leverage these relationships and infrastructure to now focus on improving rates of timely diagnostic colonoscopy follow up after an abnormal home stool screening.",[225,26],[606,607,608],"Mobile Health Technology","Telehealth","Digital Outreach","2025-09-24",{"date":586,"type":35},{"date":612,"type":20},"2025-12",{"date":614,"type":20},"2026-12",{"name":240,"class":66},{"id":617,"slug":618,"hasResults":11,"nctId":619,"briefTitle":620,"officialTitle":621,"acronym":4,"eligibilityCriteria":622,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":623,"targetDuration":4,"studyType":21,"phases":625,"briefSummary":626,"conditions":627,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":628,"lastUpdatePostDateStruct":629,"startDateStruct":631,"completionDateStruct":633,"leadSponsor":634,"locationsCount":241},"100603225","phase-2-pm8002-bnt327-in-combination-with-chemotherapy-in-patients-with-metastatic-colorectal-cancer-100603225","NCT07133750","PM8002 (BNT327) in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer","A Phase II, Multicenter, Open Label, Parallel Cohort Clinical Trial to Evaluate the Efficacy and Safety of PM8002 (BNT327) in Combination With Chemotherapy in First Line MSS or MSI-L\u002FpMMR Metastatic Colorectal Cancer","Key Inclusion Criteria:\n\n1. Signed informed consent form before any trial-related processes.\n2. Age ≥ 18 years male or female.\n3. Histologically or cytologically confirmed metastatic colorectal cancer (stage IV, UICC\u002FAJCC staging system) that is not suitable for or cannot be radically resected surgically.\n4. Participants must not have dMMR or MSI-H.\n5. No prior systemic anti-tumor therapy for metastatic colorectal cancer.\n6. have adequate organ function.\n7. The investigator confirms at least one measurable lesion according to RECIST v1.1. A measurable lesion located in the field of previous radiation therapy or after local treatment may be selected as a target lesion if progression is confirmed.\n8. The Eastern Cancer Cooperative Group (ECOG) performance score of 0 or 1.\n\nKey Exclusion Criteria:\n\n1. Received the following treatments or medications prior to starting study treatment:\n\n   1. Received palliative local therapy, non-specific immunomodulatory therapy, or chineses herbal therapy with an anti-tumor indication within 14 days prior to study treatment.\n   2. Treatment with systemic glucocorticoids (prednisone \\>10 mg\u002Fday or equivalent dose of other glucocorticoids) or other immunosuppressive agents within 14 days prior to initiation of study treatment. Note: treatment with local, intraocular, intra-articular, intranasal, and inhaled glucocorticosteroids and short-term prophylactic use of glucocorticoids (e.g., to prevent allergy to contrast agent) are allowed.\n2. Have a major coagulation disorder or other evidence of significant bleeding risk.\n3. Adverse effects of prior antitumor therapy have not returned to a CTCAE 5.0 grade rating of ≤ grade 1\n4. Have a serious non-healing wound, ulcer, or bone fracture.\n5. History of abdominal fistula, gastrointestinal perforation, or abdominal abscess, history of gastrointestinal obstruction, or clinical signs of gastrointestinal obstruction within 6 months prior to initiation of study treatment.\n6. Severe uncontrollable intra-abdominal inflammation that requires clinical intervention, in the judgment of the investigator.\n7. Have uncontrolled hypertension or poorly controlled diabetic conditions prior to study treatment.",{"count":624,"type":20},40,[331],"PM8002 (BNT327) is a bispecific antibody targeting PD-L1 and VEGF. This is a phase II trial to evaluate the efficacy and safety of PM8002 in combination with chemotherapy in first line MSS or MSI-L\u002FpMMR metastatic colorectal cancer.",[26],"2025-08-13",{"date":630,"type":35},"2025-08-21",{"date":632,"type":20},"2025-08",{"date":115,"type":20},{"name":635,"class":42},"Biotheus Inc.",{"id":637,"slug":638,"hasResults":11,"nctId":639,"briefTitle":640,"officialTitle":641,"acronym":4,"eligibilityCriteria":642,"healthyVolunteers":249,"sex":16,"minAge":643,"maxAge":4,"enrollmentInfo":644,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":645,"conditions":646,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":647,"startDateStruct":649,"completionDateStruct":651,"leadSponsor":653,"locationsCount":241},"100595492","an-exploratory-study-on-gene-methylation-detection-of-colorectal-cancer-100595492","NCT07033156","An Exploratory Study on Gene Methylation Detection of Colorectal Cancer","An Exploratory Study on Gene Methylation Detection of Colorectal Cancer（CRC）","Inclusion Criteria:\n\n1. Sample Source: Hospital physical examination, outpatient, and inpatient patients;\n2. Patient Information: Patient information (such as age, hospital ID number, gender, clinical diagnosis, colonoscopy and pathology results) is traceable;\n3. Age Requirement: ≥ 40 years old;\n4. Sampling Time Requirement: Stool and plasma samples must be collected within 3 months prior to colonoscopy (stool samples are preferred).\n\nExclusion Criteria:\n\n1. Unclear Sample Collection Information: Samples with unclear collection time, or stool samples not collected within 3 months prior to colonoscopy, or samples with incomplete clinical information that cannot be traced;\n2. Non-compliance with Sample Requirements: Samples that do not meet the collection and storage requirements;\n3. History of Disease: Subjects with a history or treatment of colorectal cancer (CRC) or advanced precancerous lesions;\n4. Insufficient Sample Volume: Samples with insufficient volume that cannot meet the requirements of the assessment system testing;\n5. Hereditary Diseases: Subjects with a diagnosis or family history of the following diseases:Familial adenomatous polyposis (FAP), including attenuated FAP and Gardner syndrome;Hereditary nonpolyposis colorectal cancer syndrome (HNPCC or Lynch syndrome);Other hereditary cancer syndromes, including but not limited to Peutz-Jeghers syndrome, MYH-associated polyposis (MAP), Turcot syndrome (or Crail syndrome), Cowden syndrome, juvenile polyposis, neurofibromatosis, or familial proliferative polyposis (FAP);\n6. Inflammatory Bowel Disease (IBD): Subjects with a diagnosis or personal history of IBD, including chronic ulcerative colitis and\u002For Crohn's disease;\n7. Cronkhite-Canada Syndrome: Subjects with a diagnosis of Cronkhite-Canada syndrome.","40 Years",{"count":577,"type":20},"The goal of this exploration study is to evaluate the performance of a colorectal cancer (CRC) early screening model based on the DNA methylation technology platform. The study focuses on individuals over the age of 40 and aims to identify and verify methylation biomarkers for colorectal cancer using stool samples . The main question it aims to answer is:\n\nCan a DNA methylation-based model effectively detect colorectal cancer and adenoma in individuals over 40 using non-invasive stool samples?\n\nParticipants will provide stool samples for methylation analysis. The study results will be used solely for internal product performance evaluation and optimization by the sponsor and will not be used for product registration or influence any clinical diagnosis.",[26,448],{"date":648,"type":35},"2025-06-29",{"date":650,"type":35},"2024-12-24",{"date":652,"type":20},"2025-10-20",{"name":654,"class":66},"Zhejiang Provincial People's Hospital",{"id":656,"slug":657,"hasResults":11,"nctId":658,"briefTitle":659,"officialTitle":659,"acronym":4,"eligibilityCriteria":660,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":661,"targetDuration":4,"studyType":21,"phases":663,"briefSummary":664,"conditions":665,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":666,"lastUpdatePostDateStruct":667,"startDateStruct":669,"completionDateStruct":671,"leadSponsor":673,"locationsCount":4},"100591814","an-exploratory-clinical-study-evaluating-the-efficacy-and-safety-of-tunlametinib-combined-with-fruquintinib-in-the-third-line-treatment-of-advanced-colorectal-cancer-patients-with-ras-mutations-100591814","NCT06985316","An Exploratory Clinical Study Evaluating the Efficacy and Safety of Tunlametinib Combined With Fruquintinib in the Third-line Treatment of Advanced Colorectal Cancer Patients With RAS Mutations.","Inclusion Criteria:\n\n1)18 years old or older, both males and females are allowed; 2)ECOG performance status of 0 or 1; 3)Histologically or cytologically proven advanced colorectal cancer; 4)Previous gene testing results indicate positive RAS mutation; 5)According to RECIST v1.1 assessment, there is at least one measurable lesion; 6)Patients who have previously failed second-line systemic antitumor therapy, and have imaging evidence of disease progression, or who are intolerant to the treatment regimen; patients who have failed front line immunotherapy are allowed to receive cross-line treatment; 7)Expected survival period \\> 3 months; 8)The main organ functions and bone marrow function are normal, meeting the following requirements:\n\n* Blood routine: Hemoglobin ≥80 g\u002FL (no blood transfusion in the last 14 days); Absolute neutrophil count ≥1.5×10\\^9\u002FL; Platelet count ≥90×10\\^9\u002FL;\n* Liver function: Alanine aminotransferase (ALT), Aspartate aminotransferase (AST) and Alkaline phosphatase (ALP) ≤2.5×upper limit of normal (ULN); if liver metastasis is present, ALT and AST ≤5×ULN, ALP ≤6×ULN; Total bilirubin ≤1.5×ULN; Albumin ≥30 g\u002FL;\n* Kidney function: Serum creatinine ≤1.5×ULN or creatinine clearance calculated by the Cockcroft-Gault formula \\>60 mL\u002Fmin;\n* Heart function: Echocardiography shows left ventricular ejection fraction (LVEF) ≥55%; ECG QTcF ≤480ms; Creatine kinase (CK) ≤1×ULN, troponin\u002Fsensitive troponin ≤1×ULN;\n* Coagulation function: International Normalized Ratio (INR) for prothrombin time ≤1.5×ULN; Activated partial thromboplastin time (APTT) ≤1.5×ULN;\n* Urinalysis: Urine protein \\\u003C2; when ≥2, a 24-hour urine protein quantification test should be performed; if the quantification test \\\u003C1g\u002F24h, they can be included in the group; if urine protein ≥1g\u002F24h, they cannot be included; if urine protein ≥2 without quantification testing, they cannot be included; 9)Able to take oral medication; 10)Women of childbearing age must undergo a pregnancy test (serum or urine) within 14 days prior to enrollment, with negative results, and voluntarily use appropriate contraception during the observation period and for 3 months after the last administration of the study drug; for men, they should be surgically sterilized or agree to use appropriate contraception during the observation period and for 3 months after the last administration of the study drug; 11)Voluntarily participate and sign the informed consent form, expected to have good compliance and be able to cooperate with the study according to the protocol requirements.\n\nExclusion Criteria:\n\n1. There are contraindications that influence investigators' choices in the use of therapeutic drugs (according to the latest drug instructions).\n2. Previously received MEK inhibitors;\n3. Within 4 weeks before the first use of the drug, underwent major surgery (excluding biopsies and minor outpatient surgeries, such as the placement of vascular access) or experienced serious trauma;\n4. There is the presence of clinically symptomatic third space effusion (such as large pleural effusion or ascites) that cannot be controlled through drainage or other methods;\n5. Subjects with symptomatic or untreated brain metastases, leptomeningeal metastases, or spinal cord compression, except for the following conditions: asymptomatic brain metastases (i.e., no progressive central nervous system symptoms caused by brain lesions, no need for corticosteroids or antiepileptic drug treatment, and imaging confirms stability of lesions for ≥4 weeks; for patients who have undergone stereotactic brain radiotherapy or surgical treatment, if there has been no disease progression in the brain for 3 months or more, they can be included;\n6. Impaired cardiac function or clinically significant cardiovascular diseases, including any of the following:\n\n   * Acute coronary syndrome occurring within 6 months prior to treatment initiation, including acute myocardial infarction, unstable angina, coronary artery bypass graft surgery, coronary angioplasty, and stent implantation;\n   * Symptomatic congestive heart failure (New York Heart Association \\[NYHA\\] class ≥ II); evidence of clinically significant arrhythmias and\u002For conduction abnormalities within 6 months prior to treatment initiation or currently;\n   * Poorly controlled hypertension (systolic blood pressure ≥ 150 and\u002For diastolic blood pressure ≥ 100 mmHg under medication control);\n   * Abnormalities in heart valve morphology recorded by echocardiography (≥ grade 2), Note: Patients with grade 1 heart valve morphology abnormalities (such as mild regurgitation\u002Fstenosis) are allowed to enroll, but patients with moderate valve thickening are prohibited from enrolling;\n   * History of congenital long QT syndrome; or taking medications known to prolong the QT interval and unable to ensure discontinuation during the study.\n7. A history of retinal diseases during the past or screening, such as: retinal vein occlusion (RVO), retinal artery occlusion, retinal vasculitis, diabetic retinopathy, hypertensive retinopathy, retinal capillary dilatation (Costs disease), retinal pigment epithelial detachment (RPED), etc.; presence of risk factors for RVO during screening (for example, uncontrolled glaucoma or high intraocular pressure, history of hyperviscosity or hypercoagulable syndromes); retinal diseases such as RPED;\n8. Interstitial lung disease or interstitial pneumonia, including patients with clinically significant radiation pneumonia (i.e., those affecting daily activities or requiring intervention treatment);\n9. Positive for human immunodeficiency virus (HIV) antibodies, positive for syphilis antibodies (Anti TP), positive for hepatitis C virus (HCV) antibodies and HCV RNA, positive for hepatitis B virus surface antigen (HBsAg) and HBV DNA (positive HBsAg requires further testing for HBV DNA, with HBV DNA ≥ 200 IU\u002Fml or ≥ 10\\^3 copies\u002Fml);\n10. A history of chronic inflammatory bowel disease or Crohn's disease requiring medical intervention (immunomodulators or surgery) within 12 months prior to the start of treatment;\n11. It is known that there is a history of acute or chronic pancreatitis within 6 months before the start of treatment;\n12. Patients with active gastrointestinal bleeding who require treatment;\n13. History of allogeneic bone marrow transplantation or organ transplantation;\n14. Within 2 weeks prior to the initial administration of the drug, there are uncontrolled active infectious diseases (e.g., requiring intravenous administration of antibiotics, antifungals, or antiviral medications), or unexplained fever \\>38.5°C occurs during the screening period \u002F before the first dose of the drug;\n15. Incurable electrolyte abnormalities (hypokalemia, hypomagnesemia, hypocalcemia detected through blood biochemical tests);\n16. Past or currently existing neuromuscular diseases related to elevated CK (such as inflammatory myopathy, muscular dystrophy, amyotrophic lateral sclerosis, spinal muscular atrophy, rhabdomyolysis syndrome);\n17. Venous or arterial thrombotic events that occurred within the first 6 months prior to the initial use of the drug, such as cerebrovascular accidents (including transient ischemic attacks, intracerebral hemorrhages, cerebral infarctions), deep vein thrombosis, and pulmonary embolism, etc.;\n18. Symptoms of grade 3 bleeding as defined by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v5.0) occurred within 4 weeks prior to the first use of the drug;\n19. Patients with a history of other malignant tumors in the past 5 years are excluded, except for those who have been completely cured of skin basal cell carcinoma or skin squamous cell carcinoma and cervical carcinoma in situ, and\u002For any malignant tumor patients who have been cured with no disease or who have been disease-free for at least 5 consecutive years;\n20. Those who are allergic to any component of this study drug are known;\n21. A clear history of neurological or psychiatric disorders, including epilepsy and dementia;\n22. Have received any of the following antitumor treatments prior to the initial study of drug administration (either on the market or in clinical trials): ① Antitumor immunotherapy within 3 weeks; ② Large molecular targeted antitumor therapy such as Bevacizumab within 3 weeks; ③ Chemotherapy or clearly antitumor traditional medicine within 2 weeks; ④ Small molecule targeted antitumor drug treatment within 2 weeks or within 5 half-lives (whichever is longer); ⑤ Subjects who have undergone palliative radiation therapy for bone metastasis within 2 weeks are excluded, but those who have received radiation treatment with an area of ≥30% of the bone marrow within 2 weeks are not allowed to be included;\n23. Before studying drug administration, all related toxic reactions from antitumor treatments (such as hair loss, skin pigmentation, grade 2 chemotherapy-related peripheral neurotoxicity, grade 2 toxicities caused by immune checkpoint inhibitors like elevated blood sugar or hypothyroidism, etc.) have not recovered to a level of ≤ grade 1 (as determined by NCI CTCAE v5.0);\n24. Patients may be used in conjunction with other anticancer drugs (bisphosphonates for the treatment of bone metastases are acceptable);\n25. Uncontrolled comorbidities, including but not limited to severe diabetes (fasting blood glucose \\> 250 mg\u002Fdl or 13.9 mmol\u002FL), or other severe diseases requiring systemic treatment;\n26. Vaccination with live vaccines or attenuated vaccines within 4 weeks prior to the first dose (Note: If enrolled, participants must not receive live vaccines during the study treatment period and within 30 days after the last dose of the investigational drug);\n27. For premenopausal female subjects (postmenopausal female patients must have been menopausal for at least 12 months to be considered infertile), a positive pregnancy test result; during the study and at least 30 days after the last administration of the study drug, females of childbearing potential who are hoping to become pregnant, breastfeeding, or unwilling to use effective contraceptive methods (including female partners of male subjects);\n28. Patients who are undergoing treatment and cannot discontinue intravenous or oral medications that have a prohibitive effect on CYP isoenzymes (strong inducers or strong inhibitors of CYP2C9 and CYP3A4) at least 1 week before starting the study treatment and during the study; patients who are taking medications with a narrow therapeutic window that are metabolized by CYP1A2;\n29. Inability to swallow capsules or refractory nausea and vomiting, malabsorption, external bile diversion, or any significant small bowel resection that may interfere with the complete absorption of the study drug;\n30. Researchers believe there are other situations that are not suitable for inclusion. For example, factors related to family or society may affect the safety of the subjects, or the collection of data and samples.",{"count":662,"type":20},34,[222],"This study is a prospective, open-label, single-arm clinical study aimed at evaluating the efficacy and safety of Tunlametinib combined with Fruquintinib in the third-line treatment of advanced colorectal cancer patients with RAS mutations.",[476],"2025-05-14",{"date":668,"type":35},"2025-05-22",{"date":670,"type":20},"2025-05-19",{"date":672,"type":20},"2028-04-27",{"name":674,"class":66},"Liu Huang",{"id":676,"slug":677,"hasResults":11,"nctId":678,"briefTitle":679,"officialTitle":680,"acronym":4,"eligibilityCriteria":681,"healthyVolunteers":249,"sex":16,"minAge":682,"maxAge":218,"enrollmentInfo":683,"targetDuration":4,"studyType":21,"phases":685,"briefSummary":686,"conditions":687,"keywords":688,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":690,"lastUpdatePostDateStruct":691,"startDateStruct":693,"completionDateStruct":695,"leadSponsor":697,"locationsCount":241},"100536144","interactive-telehealth-intervention-to-increase-longitudinal-adherence-to-repeat-faecal-immunochemical-test-screening-100536144","NCT06261008","Interactive Telehealth Intervention to Increase Longitudinal Adherence to Repeat Faecal Immunochemical Test Screening","Utilization of a Theory-driven, Culturally Tailored, Social Media-based, Interactive Telehealth Intervention to Increase Longitudinal Adherence to Repeat Faecal Immunochemical Test Screening: A Randomized Controlled Trial","Inclusion Criteria:\n\n* 50-75 years old\n* already enrolled in the Program with negative FIT results in 2022\n* eligible for the Program inclusion and due for repeat FIT screening in 2024\n* either the participants themselves or their family members \u002F caregivers have access to and agree to be contacted via WhatsApp\n* ability to understand Chinese\n\nExclusion Criteria:\n\n* who have incomplete conversations with the chatbot, lack of access to WhatsApp, or are unable to provide informed consent will be excluded","50 Years",{"count":684,"type":20},370,[222],"In Hong Kong, Colorectal cancer ranks second in both cancer incidence and mortality. The government-subsidized population-based CRC screening program (the Program) was launched for asymptomatic individuals aged 50-75 years to undergo biennial FIT screenings. A subsidized follow-up colonoscopy is offered to participants with positive FIT results. Participants are advised to repeat the FIT screening 2 years after receiving a negative result. An automated noninteractive short message service (SMS) text reminder, used by the Program as standard care (SC), is delivered to participants who are due for repeat FIT. According to unpublished data, despite SC, only 34% of participants adhere to biennial repeat FIT in the CRC screening program. Nonadherence to repeat FIT screening is caused by forgetfulness and is associated with an individual's psychological health behaviour.",[476],[689],"colorectal cancer, screening, fecal immunochemical test","2024-05-16",{"date":692,"type":35},"2024-05-17",{"date":694,"type":20},"2024-06-01",{"date":696,"type":20},"2026-06-26",{"name":268,"class":66}]